Attovia Therapeutics

Attovia Therapeutics is a San Carlos, California clinical-stage biotech developing first-in-class multispecific biologics for immune-mediated diseases. Its proprietary ATTOBODY platform builds small-format, biparatopic nanobody medicines with ultra-high (picomolar) affinity, tunable half-life and fast tissue penetration - engineered to hit multiple disease pathways at once. Lead programs ATTO-1310 (anti-IL-31) and ATTO-3712 (IL-13 x IL-31 bispecific) target chronic pruritus and atopic dermatitis. Founded in 2023 out of an Alamar Biosciences and Frazier Life Sciences incubation, the company has raised roughly $255M across Series A through C.